Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive pharmacokinetics results for First Horizon drug
Triglide is a fibric acid derivative, which is an adjunctive therapy to diet for high cholesterol and high levels of triglyceride in the blood. First Horizon licensed the
Triglide is a fibric acid derivative, which is an adjunctive therapy to diet for high cholesterol and high levels of triglyceride in the blood. First Horizon licensed the
Under the collaboration scientists will use Orion’s methylation technologies to identify biomarkers useful in the detection and treatment of cancers of the lung, breast and ovaries. Methylation refers
In one double-blind, placebo-controlled study in irritable bowel syndrome (IBS), 57% of the participants noted a significant reduction in abdominal pain and bloating after taking Ganeden’s IBS treatment,
After identifying NTx-265 as its lead compound, completing dosing in a phase I study, and raising $8.5 million in an initial public offering, Stem Cell Therapeutics (SCT) has
ATL-962, discovered by Alizyme, is an inhibitor of gastrointestinal lipases and an agent to treat obesity and diabetes. It is designed to cause weight loss by reducing the
The trial will take place in the US and Canada investigating the safety, tolerability and efficacy of EDP-420, an investigational bridged bicyclic macrolide antibiotic for the treatment of
The study evaluated the effects of a single dose of Merck & Co’s Zocor (simvastatin), Pfizer’s Lipitor (atorvastatin calcium), and Kos Pharmaceuticals’ Niaspan (niacin) on the pharmacokinetics and
The study, being funded by a Small Business Technology Transfer (STTR) grant totaling $1.4 million, will assess adult derived hemangioblasts (stem cells) in chronic ischemia, a serious form
Pfizer’s net income for Q4 2005 fell 3% to $2.7 billion, compared to Q4 2004, with revenue for the quarter down 9% compared to the previous year. However,
As a drug development company, CombinatoRx Singapore intends to focus on developing a range of preclinical and clinical development capabilities using CombinatoRx’ combination high throughput screening (cHTS) technology.